Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Nov 2019
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). ⋯ In this post hoc analysis of patients with UC, during tofacitinib exposure, one patient had DVT and four had PE, all during the OLE study, on predominant dose 10 mg b.d. (83% of overall cohort patients received predominant dose 10 mg b.d.) with venous thromboembolism risk factors. This analysis is limited by small sample size and limited drug exposure; further studies are needed. ClinicalTrials.gov: NCT00787202, NCT01465763, NCT01458951, NCT01458574, NCT01470612.
-
Aliment. Pharmacol. Ther. · Nov 2019
Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients.
Severe and fulminant Clostridioides difficile infection is associated with high mortality rates. While faecal microbiota transplant has been shown to be effective for recurrent C difficile infection, there is little data on the utility of faecal microbiota transplant in severe or fulminant C difficile infection. ⋯ Faecal microbiota transplantation provides mortality benefit over standard of care for severe and fulminant C difficile infection and should be considered in critically ill patients.